Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc. (IMPL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
impl · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Impel Pharmaceuticals Inc. (IMPL) measures how much investors pay for each dollar of the company's trailing earnings. IMPL's current PE ratio of N/A is calculated by dividing its stock price of $0.04 by its TTM earnings per share of -$5.52.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2019 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Impel Pharmaceuticals Inc.You IMPL | $1M | N/A | — | -$5.52 |
 Acorda Therapeutics, Inc. ACOR | $1M | N/A | — | -$203.59 |
 Accelerate Diagnostics, Inc. AXDX | $1M | N/A | — | -$2.15 |
 Bellicum Pharmaceuticals, Inc. BLCM | $1M | N/A | — | -$0.81 |
 CohBar, Inc. CWBR | $1M | N/A | — | -$4.13 |
 Altamira Therapeutics Ltd. CYTO | $1M | N/A | — | $0.00 |
 Infinity Pharmaceuticals, Inc. INFIQ | $0M | N/A | — | -$0.50 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-5.52 | — | |
2021-12-31 FY2021 | — | $-5.24 | — | |
2020-12-31 FY2020 | — | $-3.49 | — | |
2019-12-31 FY2019 | — | $-3.19 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Impel Pharmaceuticals Inc. (IMPL) measures how much investors pay for each dollar of the company's trailing earnings. IMPL's current PE ratio of N/A is calculated by dividing its stock price of $0.04 by its TTM earnings per share of -$5.52.
Frequently asked questions
IMPL pe ratio · 6 questionsIMPL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.04 and TTM EPS of -$5.52. Data sourced from Financial Modeling Prep via IMPL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Impel Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09